Basic Information
ID DDInter174
Drug Type small molecule
Molecular Formula C15H14N2O4S
Molecular Weight 318.350
CAS Number 866323-14-0
Description Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
ATC Classification L01XH04
IUPAC Name (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
InChI NCNRHFGMJRPRSK-MDZDMXLPSA-N
Canonical SMILES ONC(=O)\C=C\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1
Useful Links DrugBank ChEBI PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC
Interactions with Belinostat
Filter:
Severity level ID Name Mechanism Detail
Interactions with diseases
Filter:
Severity level Disease name Text References
Interactions with foods
Filter:
Severity level Food name Description Management Mechanism References
Interactions with compound preparation
Multi-DRUG trade Multi-DRUG Drug type Warning Note